|
Search
Collections
Benchmarks
Upload document
Achondroplasia Benchmark Table
Refractory melanoma Benchmark Table
Squamous lung cancer
Refractory cancer pain Benchmark Table
Stage II/III melanoma Benchmark Table
Advanced FAP-expressing solid tumors Benchmark Table
Advanced soft tissue sarcomas Benchmark Table
Locally advanced, resectable gastric/gastric junction adenocarcinoma with HER2 overexpression Benchmark Table
Metachronous metastatic esophagogastric cancer Benchmark Table
Metastatic renal cell carcinoma with sarcomatoid differentiation Benchmark Table
Clear cell renal cell carcinoma with inferior vena cava tumor thrombus Benchmark Table
Non-G12C KRAS-mutant non-small cell lung cancer Benchmark Table
Advanced NSCLC with HER-2 mutations/amplification Benchmark Table
High-risk muscle-invasive urothelial carcinoma Benchmark Table
Hand-foot syndrome Benchmark Table
Carcinoma Gall bladder Benchmark Table
Ovarian cancer with BRCA1/HR mutations Benchmark Table
Solid tumors with BRCA2 and/or PALB2 mutation Benchmark Table
Early-stage colon cancer Benchmark Table
Pancreas, breast, and metastatic prostate cancers Benchmark Table
Locally advanced prostate cancer or metastatic hormone-sensitive prostate cancer Benchmark Table
Locally advanced oral squamous cell carcinoma (LA-OSCC) Benchmark Table
Non-clear cell renal cell carcinoma Benchmark Table
FGFR+ Muscle Invasive Bladder Cancer Benchmark Table
Resectable gastric carcinoma Benchmark Table
Limited Disease Small Cell Lung Cancer Benchmark Table
Pancreatic cancer with pulmonary oligometastases Benchmark Table
Recurrent or metastatic pancreatic cancer Benchmark Table
Febrile neutropenia in cancer patients Benchmark Table
Chemoradiotherapy-induced thrombocytopenia Benchmark Table
Oligometastatic castration-resistant prostate cancer Benchmark Table
Leiomyosarcoma Benchmark Table
Chondrosarcoma Benchmark Table
SMARCA4 mutant non-small cell lung cancer Benchmark Table
Advanced chordoma Benchmark Table
Tenosynovial Giant Cell Tumor (TGCT) Benchmark Table
IDH-mutant gliomas Benchmark Table
Advanced soft tissue sarcoma Benchmark Table
Polycythemia vera and Essential thrombocytopenia with Type 2 Diabetes Mellitus Benchmark Table
Advanced Gastroesophageal Adenocarcinoma Benchmark Table
Prostate cancer with COVID-19 Benchmark Table
Prostate cancer without CDK12 alteration Benchmark Table
BRAFV600E-positive radioiodine resistant differentiated thyroid cancer Benchmark Table
Anaplastic thyroid cancer Benchmark Table
HER2+ metastatic gastroesophageal adenocarcinoma Benchmark Table
HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma Benchmark Table
Unresectable locally advanced melanoma Benchmark Table
Elevated PSA Benchmark Table
De novo metastatic castration-sensitive prostate cancer Benchmark Table
Unresectable locally advanced/locally recurrent esophageal cancer or esophagogastric junction cancer Benchmark Table
Cancer-related insomnia Benchmark Table
Gastric cancer, Pancreatic cancer Benchmark Table
Adrenocortical cancer Benchmark Table
Locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation Benchmark Table
Resectable locally advanced head and neck squamous cell carcinoma Benchmark Table
HER2 mutant/amplified NSCLC Benchmark Table
Squamous cell carcinoma of unknown primary (SCCUP) Benchmark Table
Advanced pancreatic ductal adenocarcinoma Benchmark Table
Recurrent small cell lung cancer Benchmark Table
ACC with NOTCH1 pathway activation Benchmark Table
Prostate cancer with Type 2 Diabetes Benchmark Table
Localized Prostate Cancer Benchmark Table
Breast Cancer and Prostate Cancer Benchmark Table
Chemotherapy-induced night sweats in pancreatic cancer Benchmark Table
Solid tumors with KRAS mutations Benchmark Table
Solid tumors with NRAS mutations Benchmark Table
Non-metastatic castrate sensitive prostate cancer Benchmark Table
Advanced gastric or gastroesophageal junction cancer Benchmark Table
Advanced and metastatic prostate cancer Benchmark Table
AR+ recurrent/metastatic salivary gland carcinoma Benchmark Table
Small cell prostate cancer (SCPC) and treatment-emergent neuroendocrine prostate cancer (tNEPC) Benchmark Table
Advanced solid tumors (ovarian, prostate, breast cancer) Benchmark Table
CLDN18.2+, HER2-, LA unresectable or mG/GEJ adenocarcinoma Benchmark Table
Hormone-naive prostate cancer with pelvic lymph node metastases Benchmark Table
MMRd recurrent/metastatic endometrial cancer Benchmark Table
PSA-recurrent, non-metastatic, non-castrate prostate cancer Benchmark Table
De novo metastatic castration-sensitive prostate cancer (mCSPC) Benchmark Table
Metastatic Neuroendocrine Prostate Cancer Benchmark Table
MSI-H metastatic castration-resistant prostate cancer Benchmark Table
High-volume metastatic hormone-sensitive prostate cancer Benchmark Table
Low-risk prostate cancer Benchmark Table
Metastatic hormone-resistant prostate cancer Benchmark Table
Metastatic castrate-resistant prostate cancer, Advanced endometrial cancer Benchmark Table
Metastatic hormone sensitive prostate cancer Benchmark Table
Advanced or metastatic prostate cancer Benchmark Table
Resectable squamous non-small cell lung cancer Benchmark Table
Benign Prostatic Hyperplasia Benchmark Table
Prostate cancer (control) Benchmark Table
Erectile dysfunction Benchmark Table
Androgenetic alopecia Benchmark Table
Relapsed or refractory multiple myeloma Benchmark Table
Non-metastatic CSPC with high-risk BCR Benchmark Table
Metastatic CSPC Benchmark Table
Advanced breast cancer with bone metastasis Benchmark Table
Heart Failure With Volume Overload Benchmark Table
Metastatic castration-sensitive prostate cancer Benchmark Table
Recurrent prostate cancer Benchmark Table
Advanced prostatic carcinoma Benchmark Table
Atherosclerosis Benchmark Table
Cardiovascular disease prevention Benchmark Table
Non-metastatic, castration sensitive prostate cancer (nmCSPC) Benchmark Table
HR positive, HER2 negative breast cancer Benchmark Table
Advanced or metastatic TMB/TML-H cancers Benchmark Table
Early-stage lung solid-predominant and micropapillary subtype adenocarcinoma Benchmark Table
Relapsed/refractory gynecological solid tumors Benchmark Table
Stage III and IV ovarian cancer Benchmark Table
HR+/HER2- metastatic breast cancer Benchmark Table
Localized sarcoma Benchmark Table
Locally advanced rectal cancer (LARC) Benchmark Table
Oropharyngeal squamous cell carcinoma Benchmark Table
DMMR irresectable or metastatic esophagogastric cancer adenocarcinoma Benchmark Table
Cancer with ERBB2 amplification/overexpression or activating ERBB2 mutations Benchmark Table
Refractory cancers in young adults and rare tumors Benchmark Table
Stage IIIC NSCLC Benchmark Table
Double expression (DE) DLBCL Benchmark Table
Advanced gastroenteropancreatic (GEP) and lung neuroendocrine tumors (NETs) Benchmark Table
Advanced G1/G2 neuroendocrine tumors Benchmark Table
Head and neck cancers Benchmark Table
Advanced solid tumors (MSS/MSI-L ovarian cancer) Benchmark Table
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) Benchmark Table
Unresectable metastatic lung cancer Benchmark Table
Relapsed/refractory germ cell tumors Benchmark Table
Recurrent or metastatic cervical cancer Benchmark Table
Goblet cell adenocarcinoma Benchmark Table
Various tissue samples Benchmark Table
HER2 negative locally advanced or metastatic breast cancer with germline BRCA 1/2 mutations Benchmark Table
RAS/BRAF wild-type metastatic colorectal cancer Benchmark Table
RAS wild-type metastatic colorectal cancer Benchmark Table
MET-altered advanced non-small cell lung cancer Benchmark Table
KRAS G12C mutant metastatic CRC Benchmark Table
FGFR2-driven solid tumors Benchmark Table
Locally advanced or metastatic HER2+ breast cancer Benchmark Table
MTAP-deleted glioblastoma Benchmark Table
Hematopoietic Stem Cell Transplantation Benchmark Table
Metastatic soft tissue sarcoma Benchmark Table
Advanced hepatocellular carcinoma Benchmark Table
Rectal squamous cell carcinoma Benchmark Table
Advanced metastatic cancer Benchmark Table
Stage IIIB NSCLC Benchmark Table
Metastatic Merkel cell carcinoma Benchmark Table
Early-stage rectal cancer Benchmark Table
MSS/MSI Colorectal Cancer and Endometrial Cancer Benchmark Table
Borderline-resectable hepatocellular carcinoma Benchmark Table
Melanoma, renal cell cancer, non-small cell lung cancer, squamous cell skin cancer, Merkel cell cancer Benchmark Table
Pan-solid tumors Benchmark Table
Salivary gland tumors Benchmark Table
KRAS G12C mutant NSCLC Benchmark Table
HR+, HER2-low metastatic breast cancer Benchmark Table
CCNE1-amplified metastatic endometrial ovarian cancer Benchmark Table
Testicular cancer Benchmark Table
Advanced rare cancers Benchmark Table
Advanced extrahepatic cholangiocarcinoma and gallbladder cancer Benchmark Table
Stage III colon cancer Benchmark Table
HR-negative, HER2 Low breast cancer Benchmark Table
HER2+ breast cancer Benchmark Table
Liver metastases Benchmark Table
Esophageal cell carcinoma Benchmark Table
Cancer screening Benchmark Table
Platinum resistant ovarian cancer with moderate/low FRα expression Benchmark Table
Hypopharyngeal squamous cell carcinoma Benchmark Table
MSS locally advanced rectal cancer Benchmark Table
Advanced OGA Benchmark Table
Locally advanced esophageal squamous cell carcinoma Benchmark Table
Advanced/recurrent solid tumours Benchmark Table
Clinical stage IIA/B seminoma Benchmark Table
Inflammatory breast cancer Benchmark Table
HER2-amplified advanced lung cancer, salivary gland cancer, or endometrial cancer Benchmark Table
DMMR/MSI-H metastatic colorectal cancer Benchmark Table
ERBB2-positive breast cancer Benchmark Table
Voice loss after head and neck cancer surgery Benchmark Table
HER2-negative, hormone-receptor positive metastatic breast cancer Benchmark Table
Pharyngeal and esophageal cancer Benchmark Table
Advanced or Metastatic Solid Tumors Benchmark Table
Locally advanced prostate cancer and oligometastatic prostate cancer Benchmark Table
Advanced solid tumors expressing FRα Benchmark Table
Advanced cutaneous squamous cell carcinoma Benchmark Table
Unresectable locally advanced head and neck squamous cell carcinoma Benchmark Table
Microsatellite stable locally advanced rectal cancer Benchmark Table
Non-metastatic breast cancer Benchmark Table
Early stage endometrial carcinoma Benchmark Table
Diffuse large B cell lymphoma (DLBCL) with HIV Benchmark Table
RAS-mutant metastatic colorectal cancer Benchmark Table
Advanced intrahepatic cholangiocarcinoma Benchmark Table
Advanced colorectal cancer Benchmark Table
Metastatic Cancer Benchmark Table
Stage IV or recurrent breast cancer Benchmark Table
ALK-rearrangement positive NSCLC Benchmark Table
Li-Fraumeni syndrome Benchmark Table
Cancer with alterations predicting anti-PD-L1/anti PD-1 sensitivity Benchmark Table
PMMR stage II/III rectal cancer Benchmark Table
Advanced urothelial carcinoma Benchmark Table
Langerhans Cell Histiocytosis Benchmark Table
Stage I-II resectable NSCLC Benchmark Table
Metastatic head and neck cancers Benchmark Table
HER2-positive biliary tract cancer Benchmark Table
Hypogonadism Benchmark Table
Cancer with type 2 diabetes mellitus Benchmark Table
Resectable stage II - III non-small cell lung cancer Benchmark Table
Resectable stage IIIB-D melanoma Benchmark Table
Cancer with aberrations predicting increased RAF-MEK-ERK pathway activity Benchmark Table
Metastatic lung cancer, metastatic colorectal cancer, hormone-positive breast cancer Benchmark Table
DMMR stage II/III rectal cancer Benchmark Table
Haematological or solid malignancies Benchmark Table
Testicular Germ Cell Tumor and Subsequent Malignant Neoplasms Benchmark Table
DLL3-expressing solid tumors Benchmark Table
Cervical cancer Benchmark Table
Early-stage aggressive breast cancer Benchmark Table
High-risk stage IIIB-IV melanoma Benchmark Table
Advanced well-differentiated grade 1/2 pancreatic neuroendocrine tumors Benchmark Table
Unresectable hepatocellular carcinoma Benchmark Table
Advanced solid tumors associated with Nectin-4 expression Benchmark Table
Advanced clear cell renal cell carcinoma (ccRCC) Benchmark Table
KRAS G12V mutated solid tumors Benchmark Table
Advanced epithelial cancers with high TROP2 expression Benchmark Table
Relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma Benchmark Table
Glioma with BRAF alterations Benchmark Table
Recurrent and metastatic endometrial cancer Benchmark Table
AR+ triple-negative metastatic breast cancer Benchmark Table
Head and neck squamous cell carcinoma with oligometastases Benchmark Table
Hypersensitivity reactions to docetaxel Benchmark Table
Locally advanced breast cancer Benchmark Table
Desmoplastic small round cell tumor (DSRCT) and Synovial sarcoma (SySa) Benchmark Table
Stage I uterine leiomyosarcomas Benchmark Table
Cytokine Release Syndrome Benchmark Table
Thymic epithelial tumors Benchmark Table
Lung cancer and lung oligometastases Benchmark Table
Advanced/metastatic solid tumors Benchmark Table
Advanced solid tumors and mature relapsed/refractory B-NHL Benchmark Table
Locally advanced melanoma Benchmark Table
Cancer Survivor Benchmark Table
Stage IV locoregionally advanced nasopharyngeal carcinoma Benchmark Table
Chemotherapy-induced peripheral neuropathy Benchmark Table
Controlled Ovarian Stimulation Benchmark Table
Advanced squamous non-small-cell lung cancer Benchmark Table
Chronic hepatitis B with various cancers Benchmark Table
Locally advanced low rectal cancer Benchmark Table
Multiply relapsed/refractory germ cell tumours Benchmark Table
Advanced/metastatic osteosarcoma Benchmark Table
Pediatric-type fusion-driven sarcoma Benchmark Table
Intermediate-risk non-muscle invasive bladder cancer Benchmark Table
Ampullary carcinoma Benchmark Table
Waldenström's Macroglobulinemia Benchmark Table
NSCLC with bone metastases Benchmark Table
HER2-enriched or triple negative breast cancer Benchmark Table
Cancer-associated venous thromboembolism Benchmark Table
Breast cancer, colorectal cancer, lung cancer Benchmark Table
Radioiodine-refractory differentiated thyroid cancer Benchmark Table
High-risk non-muscle invasive bladder cancer Benchmark Table
Dedifferentiated liposarcoma Benchmark Table
Oesophageal squamous cell carcinoma Benchmark Table
Extensive-stage SCLC Benchmark Table
Muscle-invasive bladder cancer (MIBC) Benchmark Table
Recurrent or metastatic nasopharyngeal cancer Benchmark Table
Advanced Endometrial Cancer Benchmark Table
Resectable Pancreatic Ductal Adenocarcinoma Benchmark Table
Cancer pain Benchmark Table
Locally advanced/metastatic cancers Benchmark Table
Advanced refractory head and neck squamous cell carcinomas Benchmark Table
Colorectal cancer screening Benchmark Table
Locally advanced pancreatic cancer Benchmark Table
Advanced small cell lung cancer or neuroendocrine carcinoma Benchmark Table
Neuroendocrine cancer Benchmark Table
Medulloblastoma Benchmark Table
Head and neck squamous cell carcinoma, non-small cell lung cancer, renal/urothelial cancer Benchmark Table
Ewing sarcoma Benchmark Table
Diffuse intrinsic pontine glioma Benchmark Table
B-cell malignancies Benchmark Table
Appendiceal carcinoma Benchmark Table
Adenocarcinoma of small intestine Benchmark Table
Oligometastatic pancreatic ductal adenocarcinoma Benchmark Table
Advanced solid tumors (MSS/MSI-L CRC) Benchmark Table
Advanced-stage cancer Benchmark Table
Primary Central Nervous System Lymphoma Benchmark Table
Advanced, unresectable progressive rectal NETG1/G2 Benchmark Table
HER2 expressing/mutated metastatic solid tumors Benchmark Table
Unresectable, non-metastatic paraganglioma/pheochromocytoma (PPGL) Benchmark Table
Brain Metastases from Metastatic Non-Seminomatous Germ Cell Tumors (NSGCT) Benchmark Table
Recurrent or metastatic head and neck squamous cell carcinoma Benchmark Table
Advanced microsatellite stable (MSS) or proficient mismatch repair (pMMR) endometrial cancer Benchmark Table
BRAF class III mutant solid tumours Benchmark Table
Stage IIIB/IIIC NSGCTs Benchmark Table
Cancer with aberrations predicting increased PI3K-AKT pathway activity Benchmark Table
Locally advanced laryngeal carcinoma Benchmark Table
Resectable stage II-IV (M0) cutaneous squamous cell carcinoma Benchmark Table
Locally advanced colon cancer Benchmark Table
Metastatic hormone-naive prostate cancer Benchmark Table
MSS mCRC Benchmark Table
Metastatic gastroesophageal adenocarcinoma Benchmark Table
Platinum resistant ovarian cancer with high FRα expression Benchmark Table
Stage 4 Colorectal Cancer Benchmark Table
Advanced lung, head and neck, bladder, ovarian, and uterine cancers Benchmark Table
BRAF class II mutant/fusion positive/intragenic deletion solid tumours Benchmark Table
Multiple malignancies Benchmark Table
SSTR-positive tumors Benchmark Table
Chronic kidney disease Benchmark Table
Hip fracture Benchmark Table
Functional impairment Benchmark Table
Sarcopenia/frailty Benchmark Table
End-stage renal disease Benchmark Table
Aging-related decline in growth hormone secretion and muscle mass Benchmark Table
Cirrhosis with sarcopenia Benchmark Table
Recurrent or progressive glioblastoma with unmethylated MGMT promoter Benchmark Table
Glioblastoma and grade III glioma Benchmark Table
Newly diagnosed, MGMT promoter hypermethylated GBM Benchmark Table
EGFR-amplified recurrent glioblastoma Benchmark Table
Newly diagnosed glioblastoma or anaplastic astrocytoma Benchmark Table
Normal brain tissue Benchmark Table
Recurrent Glioblastoma Benchmark Table
Refractory anaplastic astrocytoma Benchmark Table
Recurrent or progressive glioblastoma Benchmark Table
Recurrent anaplastic glioma Benchmark Table
Recurrent Glioblastoma, Non-Small Cell Lung Cancer Benchmark Table
Methylated O6-methylguanine-DNA-methyltransferase (mMGMT) newly diagnosed glioblastoma multiforme Benchmark Table
Unmethylated O6-methylguanine-DNA-methyltransferase (uMGMT) newly diagnosed glioblastoma multiforme Benchmark Table
Glioblastoma Benchmark Table
Advanced esophageal squamous cell carcinoma Benchmark Table
Recurrent high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer Benchmark Table
Metastatic ocular melanoma Benchmark Table
Recurrent/progressive ovarian cancer, pancreatic cancer, and mesonephric-like adenocarcinoma (MLA) Benchmark Table
Advanced melanoma with lung metastasis Benchmark Table
Melanoma or lung cancer without autoimmune disease Benchmark Table
Advanced, metastatic solid tumors Benchmark Table
Advanced lung cancer or melanoma Benchmark Table
Unresectable malignant pleural mesothelioma Benchmark Table
High grade serous ovarian cancer, triple negative breast cancer Benchmark Table
Acute Myocardial Infarction Benchmark Table
Acromegaly Benchmark Table
Breast and ovarian cancer prevention Benchmark Table
High-risk ocular melanoma Benchmark Table
Ovulatory dysfunction Benchmark Table
Recurrent advanced ovarian cancer Benchmark Table
Advanced renal cell carcinoma and ovarian cancer Benchmark Table
Melanoma with liver metastasis Benchmark Table
Relapsed or refractory ovarian cancer Benchmark Table
Hereditary breast/ovarian cancer Benchmark Table
Melanoma or lung cancer with autoimmune disease Benchmark Table
Newly diagnosed Ph+ ALL Benchmark Table
Stage I MOGCTs (IC yolk sac tumors and mixed IC2 with yolk sac tumors) Benchmark Table
Platinum-sensitive recurrent ovarian carcinoma Benchmark Table
RAS or RAF mutated solid tumors Benchmark Table
Breast cancer and melanoma Benchmark Table
Advanced melanoma, mesothelioma, pancreatic cancer, colorectal cancer, non-small cell lung cancer Benchmark Table
Advanced high-grade ovarian cancer Benchmark Table
Off-target cancers Benchmark Table
Follicular lymphoma Benchmark Table
Recurrent high-grade ovarian, fallopian tube and primary peritoneal cancer Benchmark Table
Recurrent ovarian, fallopian tube, or primary peritoneal cancer Benchmark Table
Overactive bladder Benchmark Table
Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Renal Cell Carcinoma, High Grade Serous Ovarian Carcinoma Benchmark Table
Metastatic ovarian cancer Benchmark Table
Advanced non-acral cutaneous melanoma Benchmark Table
Adnexal mass Benchmark Table
Stage I MOGCTs (IA dysgerminoma and IAG1 immature teratoma) Benchmark Table
Amenorrhea and galactorrhea Benchmark Table
Unresectable platinum resistant ovarian cancer Benchmark Table
Fallopian tube cancer Benchmark Table
Systemic sclerosis Benchmark Table
Early stage epithelial ovarian cancer Benchmark Table
Early breast cancer Benchmark Table
Chemotherapy-induced nausea and vomiting Benchmark Table
Advanced ovarian cancer and colorectal cancer Benchmark Table
Cutaneous malignancies Benchmark Table
Platinum-resistant recurrent ovarian carcinoma Benchmark Table
Advanced or recurrent ovarian cancer with PARPi-related fatigue Benchmark Table
Stage IB/IIA cutaneous melanoma Benchmark Table
Recurrent low-grade serous ovarian cancer Benchmark Table
BRAF V600E mutation-positive low-grade glioma Benchmark Table
Endometrial cancer without VTEC Benchmark Table
Metastatic melanoma and Merkel cell carcinoma Benchmark Table
Platinum-resistant ovarian clear cell carcinoma Benchmark Table
Unresectable ovarian cancer Benchmark Table
Pediatric melanoma Benchmark Table
BRAF wildtype metastatic melanoma Benchmark Table
High-risk stage III melanoma Benchmark Table
Advanced-stage, relapsed/refractory melanoma Benchmark Table
Gynecological Carcinosarcoma Benchmark Table
HR-positive breast cancer Benchmark Table
Recurrent ovarian cancer, triple-negative breast cancer Benchmark Table
ER+HER2- breast cancer Benchmark Table
HR+/HER2- early-stage breast cancer Benchmark Table
Ankylosing spondylitis Benchmark Table
Resected stage III/IV melanoma Benchmark Table
Advanced HRD high-grade ovarian cancer Benchmark Table
BRAF V600E mutation-positive anaplastic thyroid cancer Benchmark Table
Advanced BRAF V600/NRAS Q61R/K/L wild-type melanoma Benchmark Table
Resected high-risk stage II melanoma Benchmark Table
Platinum-resistant/refractory epithelial ovarian cancer Benchmark Table
Neuroblastoma Benchmark Table
Clinical stages IIIB-IIID melanoma Benchmark Table
Dermatomyositis Benchmark Table
Unresectable/metastatic melanoma Benchmark Table
Metastatic breast, pancreas, prostate, and ovarian cancer Benchmark Table
Advanced Epithelial Ovarian Cancer Benchmark Table
Advanced malignancies Benchmark Table
Stage I high-grade serous ovarian cancer Benchmark Table
High-grade stage III/IV ovarian cancer Benchmark Table
Actinic keratosis Benchmark Table
Resectable stage IIIB/IV BRAF wild-type melanoma Benchmark Table
Recurrent epithelial ovarian cancer Benchmark Table
Stage II cutaneous melanoma Benchmark Table
BRAF-mutated, unresectable locally advanced stage III or oligometastatic stage IV melanoma Benchmark Table
Platinum sensitive epithelial ovarian cancer Benchmark Table
Benign, precancerous and preinvasive malignant uterine diseases Benchmark Table
Advanced acral melanoma Benchmark Table
Platinum-resistant high-grade serous ovarian cancer Benchmark Table
Alopecia areata Benchmark Table
Recurrent ovarian, fallopian tube and primary peritoneal cancer Benchmark Table
Advanced acral lentiginous melanoma Benchmark Table
Advanced or recurrent ovarian cancer Benchmark Table
High-grade serous ovarian cancer (HGSOC) Benchmark Table
Recurrent endometrial cancer or ovarian cancer Benchmark Table
Chronic neurogenic pain Benchmark Table
Adult-type ovarian granulosa cell tumors Benchmark Table
NRAS wildtype cutaneous melanoma Benchmark Table
HRD-positive recurrent platinum-resistant epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer Benchmark Table
Advanced non-melanoma cutaneous carcinoma Benchmark Table
High-risk stage IIIB–IV cutaneous melanoma Benchmark Table
None Benchmark Table
KIT-mutated melanoma Benchmark Table
High grade serous ovarian cancer and metastatic triple-negative breast cancer Benchmark Table
Advanced melanoma of unknown primary Benchmark Table
NRAS G12/13 mutant cutaneous melanoma Benchmark Table
Advanced melanoma, small cell lung cancer, or non-small cell lung cancer Benchmark Table
Pregnancy-associated melanoma Benchmark Table
NF1-mutant melanoma Benchmark Table
BRAF V600E mutation-positive metastatic NSCLC Benchmark Table
Postmenopausal hormone therapy Benchmark Table
Advanced and refractory melanoma Benchmark Table
Recurrent ovarian cancer Benchmark Table
Normal Fallopian tube epithelium Benchmark Table
Stage II melanoma Benchmark Table
High grade serous ovarian carcinoma Benchmark Table
Advanced acral and mucosal melanoma Benchmark Table
Resectable Stage IIB-IV melanoma Benchmark Table
Low-grade serous ovarian cancer Benchmark Table
Melanoma and Merkel Cell Carcinoma Benchmark Table
Resected stage IIB or IIC cutaneous melanoma Benchmark Table
Chronic Phase CML Benchmark Table
Psoriatic Arthritis Benchmark Table
Advanced melanoma with known primary Benchmark Table
Systemic Lupus Erythematosus Benchmark Table
Locally advanced or oligometastatic melanoma Benchmark Table
Esophageal Candidiasis Benchmark Table
Benign ovarian tissue Benchmark Table
Recurrent PARPi-resistant ovarian cancer Benchmark Table
Atypical Spitz tumors and Spitz melanoma Benchmark Table
GD2-expressing melanoma Benchmark Table
Melanoma Benchmark Table
Benign pelvic tumors Benchmark Table
Ovarian Cancer Benchmark Table
Breast cancer, ovarian cancer, endometrial cancer Benchmark Table
Melanoma with chronic neurogenic pain Benchmark Table
Familial melanoma Benchmark Table
Advanced Melanoma with concomitant Chronic Lymphocytic Leukemia Benchmark Table
Melanoma, rhabdomyosarcoma, or other solid tumor Benchmark Table
Resected high-risk stage III/IV cutaneous melanoma Benchmark Table
Resectable stage IIIB/IV BRAF-mutant melanoma Benchmark Table
Triple-negative breast cancer Benchmark Table
Restless Legs Syndrome Benchmark Table
Stage IIB/C melanoma Benchmark Table
Atypical melanoma Benchmark Table
NF1-mutant advanced melanoma Benchmark Table
Resected stage III/IV BRAF V600-mutated melanoma Benchmark Table
Newly diagnosed advanced ovarian cancer Benchmark Table
Papillary thyroid cancer Benchmark Table
Ovarian cancer Benchmark Table
Malignant mesothelioma Benchmark Table
Endometrial cancer Benchmark Table
Desmoid tumor Benchmark Table
Unresectable metastatic melanoma Benchmark Table
Non-serous epithelial ovarian cancer Benchmark Table
Metastatic cutaneous melanoma Benchmark Table
Advanced SCCHN and Ovarian cancer Benchmark Table
Healthy Subjects Benchmark Table
Nonsegmental Vitiligo Benchmark Table
Clear Cell Carcinoma Benchmark Table
Crohn's disease Benchmark Table
Refractory/relapsed cancer Benchmark Table
Candidemia Benchmark Table
Moderate-to-severe plaque psoriasis Benchmark Table
Relapsed ER positive ovarian cancer or endometrial cancer Benchmark Table
Stage I Mucinous Ovarian Cancer Benchmark Table
Secondary progressive multiple sclerosis Benchmark Table
Stage III/IV resectable melanoma Benchmark Table
Stage I Clear Cell Ovarian Cancer Benchmark Table
Immune-related adverse events in melanoma or non-small cell lung cancer Benchmark Table
Stage I Endometrioid Ovarian Cancer Benchmark Table
Endometrial and ovarian cancer Benchmark Table
Pregnancy Prevention Benchmark Table
Unresectable or metastatic melanoma Benchmark Table
Ovarian cancer, primary peritoneal cancer, fallopian tube cancer Benchmark Table
Ovarian vein thrombosis Benchmark Table
Soft tissue sarcoma, Bone sarcoma, Osteosarcoma, Platinum-resistant ovarian cancer Benchmark Table
Invasive aspergillosis Benchmark Table
Chronic insomnia Benchmark Table
Erdheim-Chester Disease Benchmark Table
Epilepsy Benchmark Table
Liver transplantation Benchmark Table
Heart transplantation Benchmark Table
Multiple myeloma Benchmark Table
Moderate to severe persistent asthma Benchmark Table
BRAF V600E Mutation-Positive Unresectable or Metastatic Melanoma Benchmark Table
Relapsing forms of MS Benchmark Table
Kidney transplantation Benchmark Table
Relapsed or refractory APL Benchmark Table
Various cancers Benchmark Table
Hypertension Benchmark Table
Corticosteroid-refractory chronic graft-versus-host disease Benchmark Table
Type 2 Diabetes Mellitus Benchmark Table
Advanced solid tumors, central nervous system lymphoma, recurrent high-grade glioma, uveal melanoma Benchmark Table
WM Benchmark Table
Coronary artery disease and chronic left ventricular systolic dysfunction Benchmark Table
Uveal melanoma Benchmark Table
B16 melanoma Benchmark Table
Pediatric solid tumors with NTRK gene fusion Benchmark Table
High-risk stage II melanoma Benchmark Table
Ulcerative colitis Benchmark Table
Steroid-refractory acute graft-versus-host disease Benchmark Table
Unresectable stage IIIB-IV melanoma Benchmark Table
Myelofibrosis Benchmark Table
Non-hodgkin lymphoma Benchmark Table
Mucosal melanoma Benchmark Table
Indolent non-hodgkin lymphoma Benchmark Table
Transient insomnia Benchmark Table
Melanoma brain metastases Benchmark Table
Acral melanoma Benchmark Table
Unresectable Melanoma Benchmark Table
Melanoma and Renal Cell Carcinoma Benchmark Table
Stage III/IV unresectable melanoma Benchmark Table
Small cell lung cancer, sarcoma, melanoma Benchmark Table
Unresectable stage III/IV melanoma Benchmark Table
Polycythemia vera Benchmark Table
Melanoma Brain Metastasis with Radiation Necrosis or Steroid-Refractory Edema Benchmark Table
Resectable stage IIIB/IIIC/IIID or IV melanoma Benchmark Table
Parkinson's disease Benchmark Table
Relapsed refractory melanoma Benchmark Table
Stage IV metastatic melanoma Benchmark Table
NRAS-mutant unresectable stage III or IV melanoma Benchmark Table
Melanoma with leptomeningeal disease Benchmark Table
Advanced melanoma or non-small cell lung cancer Benchmark Table
BRAF-mutant melanoma Benchmark Table
Stage III melanoma Benchmark Table
Stage IIIA melanoma Benchmark Table
Chronic Lymphocytic Leukemia Benchmark Table
Ischemic Stroke Benchmark Table
Rheumatoid Arthritis Benchmark Table
HER2-negative locally advanced or metastatic breast cancer Benchmark Table
Prostate cancer Benchmark Table
Non-metastatic castration-resistant prostate cancer Benchmark Table
NSCLC, melanoma Benchmark Table
EGFRm+ NSCLC with CNS metastasis Benchmark Table
Non-squamous EGFR wildtype NSCLC with c-Met protein overexpression Benchmark Table
EGFR-negative refractory advanced NSCLC Benchmark Table
Pulmonary inflammatory disease Benchmark Table
Metastatic non-small cell lung cancer Benchmark Table
NSCLC with HER2 exon 20 insertion mutations Benchmark Table
Stage I/II unresectable NSCLC Benchmark Table
Advanced NSCLC without EGFR-activating mutations Benchmark Table
Advanced NSCLC with KRAS mutation Benchmark Table
Non-cancerous lung lesions Benchmark Table
Advanced NSCLC and HNSCC Benchmark Table
Late stage lung squamous cell carcinoma Benchmark Table
Advanced NSCLC with PD-L1 ≥50% Benchmark Table
Unresectable stage III NSCLC with EGFR mutation Benchmark Table
EGFR-mutant T790M-positive non-small cell lung cancer Benchmark Table
EGFR-mutated advanced NSCLC with atypical mutations Benchmark Table
ALK-positive NSCLC Benchmark Table
Advanced non-squamous NSCLC Benchmark Table
Healthy controls Benchmark Table
EGFR-TKI resistant advanced NSCLC Benchmark Table
Intracranial disease progression in brain metastases from NSCLC Benchmark Table
Non-small cell lung cancer with cachexia Benchmark Table
ROS1-rearranged NSCLC Benchmark Table
Stage III unresectable NSCLC with EGFR mutations Benchmark Table
Inoperable stage III NSCLC Benchmark Table
EGFR-mutant, T790M−, MET-amplified NSCLC Benchmark Table
Advanced or metastatic NSCLC, TNBC, or SCCHN Benchmark Table
NSCLC with EGFR exon 19 deletion or L858R Benchmark Table
Resectable NSCLC Benchmark Table
Advanced squamous NSCLC Benchmark Table
RET fusion-positive NSCLC Benchmark Table
Stage I NSCLC Benchmark Table
Advanced PD-L1 negative NSCLC Benchmark Table
NSCLC with other uncommon non-ex20ins EGFR mutations Benchmark Table
Advanced NSCLC and melanoma Benchmark Table
Non-small lung cancer Benchmark Table
Stage IV NSCLC Benchmark Table
NSCLC with high-level MET amplification Benchmark Table
Early-stage non-small cell lung cancer Benchmark Table
RET-altered NSCLC, medullary thyroid cancer, or other solid tumors Benchmark Table
Advanced-stage, anti-PD1/PD-L1 relapsed/refractory solid tumors Benchmark Table
NSCLC with EGFR exon 20 insertion mutations Benchmark Table
EGFR-mutated, c-Met overexpressing NSCLC Benchmark Table
EGFR ex20ins-mutant NSCLC Benchmark Table
Stage III non-small cell lung cancer Benchmark Table
Recurrent stage III NSCLC Benchmark Table
Urothelial carcinoma Benchmark Table
Unknown primary cancer Benchmark Table
MET exon 14 skipping NSCLC Benchmark Table
EGFR-mutant NSCLC with brain metastases Benchmark Table
Relapsed/refractory NSCLC Benchmark Table
Normal lung tissue Benchmark Table
Stage I/II unresectable EGFR-mutated NSCLC Benchmark Table
Advanced melanoma Benchmark Table
Metastatic EGFR-mutated NSCLC Benchmark Table
Locally advanced/metastatic c-Met overexpressing EGFR WT nonsquamous NSCLC Benchmark Table
NSCLC with EGFR mutations and ALK rearrangements with brain metastases Benchmark Table
BRAF-mutant NSCLC Benchmark Table
Unresectable stage III non-small cell lung cancer Benchmark Table
NSCLC, mesothelioma, or ovarian cancer Benchmark Table
Unresected stage I or II NSCLC Benchmark Table
Advanced/metastatic NSCLC wild-type for EGFR, ALK and ROS1 Benchmark Table
KRAS G12D-mutant NSCLC Benchmark Table
NSCLC and pancreatic cancer Benchmark Table
Stage IIIA NSCLC Benchmark Table
NSCLC with brain metastases Benchmark Table
NTRK fusion-positive NSCLC Benchmark Table
KRAS G12C-mutated NSCLC Benchmark Table
Resectable stage IIIA NSCLC Benchmark Table
NSCLC with leptomeningeal metastases Benchmark Table
Unresectable stage IIIA/IIIB NSCLC Benchmark Table
Advanced EGFR-mutated NSCLC Benchmark Table
Non-Small Cell Lung Cancer Benchmark Table
Advanced adenocarcinoma of the lung Benchmark Table
EGFR exon 18-mutant NSCLC Benchmark Table
KRAS G12C wild-type NSCLC Benchmark Table
EGFR-mutant NSCLC with osimertinib resistance Benchmark Table
Advanced Non-sq NSCLC with EGFR and TP53 mutations Benchmark Table
Advanced melanoma and non-small cell lung cancer Benchmark Table
Advanced non-small cell lung cancer with actionable driver oncogenes Benchmark Table
Stage 1B EGFR+ NSCLC Benchmark Table
Unresectable stage 3 NSCLC Benchmark Table
Advanced NSCLC with EGFR mutation Benchmark Table
KRAS G12C-mutated solid tumors Benchmark Table
HRG+ lung adenocarcinoma Benchmark Table
Stage 4 non-squamous non-small cell lung cancer Benchmark Table
Resectable EGFRm Stage IB–IIIA NSCLC Benchmark Table
Locally advanced non-small cell lung cancer Benchmark Table
Acute Myeloid Leukemia Benchmark Table
Chronic angina Benchmark Table
Chronic myelomonocytic leukemia Benchmark Table
Vulvar and vaginal atrophy Benchmark Table
GIST Benchmark Table
Vasomotor symptoms Benchmark Table
Metastatic solid tumor other than breast or prostate cancer Benchmark Table
Multiple myeloma or metastatic breast cancer Benchmark Table
Hypercalcemia of malignancy Benchmark Table
Mild to moderate atopic dermatitis Benchmark Table
Renal Cell Carcinoma Benchmark Table
Juvenile myelomonocytic leukemia Benchmark Table
Metastatic breast cancer Benchmark Table
Pancreatic cancer Benchmark Table
NSCLC Benchmark Table
Localized Resectable Tumor, MSI/dMMR or EBV-positive Gastric Cancers Benchmark Table
Advanced gynecologic cancers Benchmark Table
Metastatic melanoma Benchmark Table
HER2-mutant non-small cell lung cancer Benchmark Table
Advanced Solid Tumor Historically Known for High EphA2 Expression Benchmark Table
Esophageal Cancer Benchmark Table
Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology Benchmark Table
Metastatic Castration-Resistant Prostate Cancer Benchmark Table
Hodgkin lymphoma Benchmark Table
Head and neck cancer Benchmark Table
Esophageal adenocarcinoma Benchmark Table
Locally Advanced Gastric Cancer Benchmark Table
Ipilimumab-Naive Melanoma Benchmark Table
HER2-low metastatic breast cancer Benchmark Table
HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma Benchmark Table
Biliary tract cancer Benchmark Table
Colorectal cancer Benchmark Table
HER2+ metastatic gastric cancer Benchmark Table
Lung cancer Benchmark Table
HER2+ early breast cancer Benchmark Table
Advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2 Benchmark Table
Metastatic colorectal cancer Benchmark Table
Small cell lung cancer Benchmark Table
Intrahepatic cholangiocarcinoma Benchmark Table
Ovarian, Breast, SCLC, Gastric Cancers Benchmark Table
Locally advanced squamous cell carcinoma of the head and neck Benchmark Table
HER2-positive metastatic breast cancer Benchmark Table
Breast cancer Benchmark Table
Advanced Solid Tumors with HER2 Expression Benchmark Table
Advanced Solid Tumors with DNA Damage Response Gene Aberrations Benchmark Table
Hepatocellular carcinoma Benchmark Table
Solid Tumors Benchmark Table
Advanced or metastatic gastrointestinal cancers (colorectal, gastric, gastroesophageal) Benchmark Table
Advanced HER2 negative gastric, esophageal, and gastroesophageal junction adenocarcinoma Benchmark Table
Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer Benchmark Table
Gastroesophageal Junction Adenocarcinoma, Gastric Cardia Adenocarcinoma Benchmark Table
Locally advanced or metastatic breast cancer Benchmark Table
Localized gastric adenocarcinoma Benchmark Table
Gastric Cancer Benchmark Table
Synovial Sarcoma Benchmark Table
HNSCC Benchmark Table
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer Benchmark Table
